BioSpace News Archive

Increasing launch of cost-efficient generic epinephrine products, growing incidence of anaphylaxis, and rising demand for epinephrine injections to treat cardiac arrest and asthma are some key factors driving market growth.

Rising prevalence of chronic diseases, such as cancer and diabetes, and growing adoption of advanced diagnostic techniques are predicted to fuel market growth.

Increased adoption of convenient home testing kits with fast and accurate results is driving rapid test kits market revenue growth.

Aptorum Group Limited announced financial results for the fiscal year ended December 31, 2021, and provided an update on clinical and corporate developments.

GENFIT announced the filing of its 2021 Universal Registration Document with the Autorité des marchés financiers and its Annual Report on Form 20-F for the year ended December 31, 2021 with the U.S. Securities and Exchange Commission, as well as the availability of preparatory documents for its annual shareholders meeting on Wednesday May 25, 2022.

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the BofA Securities 2022 Healthcare Conference on Wednesday, May 11, 2022 at 12:00 p.m. Pacific Time.

First Wave BioPharma, Inc. announced that James Sapirstein, Chairman, President and CEO First Wave BioPharma, has issued a Letter to Shareholders to provide an update on recent events and an outlook for the Company’s clinical programs in 2022.

Sarepta Therapeutics, Inc. granted equity awards on April 29, 2022 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 44 individuals hired by Sarepta in April 2022.

Myovant Sciences (NYSE: MYOV) today announced that the European Commission (EC) has approved the marketing authorisation application for ORGOVYX® (relugolix, 120 mg) for the treatment of adult patients with advanced hormone-sensitive prostate cancer.

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), will hold a webcast on Monday, May 2, 2022 at 5:00am PT/8:00am ET to review the topline results from the Saturn-2 Phase 3 trial for TP-03 (lotilaner ophthalmic solution, 0.25%) for the treatment of Demodex blepharitis and provide a brief corporate update.